

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 307/79, 405/12, A61K 31/445,</b> <b>C07D 453/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/33186</b> <b>(43) International Publication Date:</b> 24 October 1996 (24.10.96)
<b>(21) International Application Number:</b> PCT/EP96/01482 <b>(22) International Filing Date:</b> 4 April 1996 (04.04.96)  <b>(30) Priority Data:</b> 9507882.0 18 April 1995 (18.04.95) GB  <b>(71) Applicant:</b> PHARMACIA S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT).  <b>(72) Inventors:</b> FANCELLI, Daniele; Via Gianella, 21, I-20152 Milano (IT). CACCIA, Carla; Via Torino, 31, I-21013 Gallarate (IT). SEVERINO, Dino; Via Magnasco Alessandro, 6, I-20100 Milano (IT). VAGHI, Fabrizio; Via Torino, 3, I-22079 Villa Guardia (IT). VARASI, Mario; Via Giambellino, 80, I-20146 Milano (IT).		<b>(81) Designated States:</b> JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> SUBSTITUTED DIHYDROBENZOFURAN DERIVATIVES AS 5-HT <sub>4</sub> AGONISTS		
<b>(57) Abstract</b>  The present invention relates to the use of substituted dihydrobenzofuran derivatives having 5-HT <sub>4</sub> receptor agonist activity, which act as therapeutic prokinetic agents in treatment of gastrointestinal disorders such as, e.g., dyspepsia, gastro-oesophageal reflux disease (GORD) or gastroparesis. The compounds of the invention can also be useful in the treatment of CNS disorders, characterized by learning and/or memory dysfunctions. Several of these substituted dihydrobenzofuran derivatives are novel compounds and, as such, constitute a further object of the invention, together with the process for their preparation and the pharmaceutical compositions containing them.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**SUBSTITUTED DIHYDROBENZOFURAN DERIVATIVES AS 5-HT<sub>4</sub> AGONISTS**

The present invention relates to the use of substituted dihydrobenzofuran derivatives which act as 5-HT<sub>4</sub> receptor agonists in the treatment of gastrointestinal disorders and CNS disorders, to certain novel compounds having 5-HT<sub>4</sub> receptor agonist activity, to a process for their preparation and to pharmaceutical compositions containing them.

10 A non classical 5-hydroxytryptamine receptor has been designed (Trends Pharmacol. Sci. (1992) 13, 141-5) as the 5-HT<sub>4</sub> receptor.

The prokinetic action of the substituted benzamide metoclopramide, which has long been in clinical use as a stimulant of gastrointestinal motility, is believed to be on the basis of its agonist effect on the 5-HT<sub>4</sub> receptor (Drug Design & Delivery (1988) 3, 273-295).

Some 5-HT<sub>4</sub> receptor agonists resulted active in appropriate animal behavioural tests for memory dysfunctions (Ghelardini et al. 19<sup>th</sup> C.I.N.P. Congress, Whashington, June 1994 ; Ghelardini et al. 10<sup>th</sup> European Society for Neurochemistry, Jerusalem, August 1994).

International patent application WO 93/16072 describes 5-


HT<sub>4</sub> receptor antagonists derived from the benzopyran, benzothiopyran or benzofuran nucleus.

International patent application WO 94/08995 relates to novel carboxylate or carboxamides of benzofuran or  
5 dibenzofuran having 5-HT<sub>4</sub> antagonist activity.

We have identified a class of substituted dihydrobenzofuran carboxylic acid derivatives which possess 5-HT<sub>4</sub> receptor agonist properties, despite their structural analogies with the closest prior art compounds such as, e.g., those  
10 disclosed in WO 93/16072 and WO 94/08995 having 5-HT<sub>4</sub> antagonist activity.

By virtue of their 5-HT<sub>4</sub> agonist activity, the compounds of the invention can be useful in all the pathologies wherein a stimulation of the 5-HT<sub>4</sub> receptors is needed and  
15 therefore, the compounds of the invention can be useful, for example, as therapeutic prokinetic agents in the treatment of gastrointestinal disorders such as, e.g., dyspepsia, gastro-oesophageal reflux disease (GORD) and gastroparesis, and/or also in the treatment of CNS  
20 disorders characterized by learning and/or memory dysfunctions.

Accordingly, the present invention relates to dihydrobenzofuran derivatives of formula (I)







wherein

$R_1$ ,  $R_2$  and  $R_3$  are, each independently, hydrogen,  $C_1$ - $C_6$  alkyl, halogen, hydroxy,  $C_1$ - $C_4$  alkoxy, amino,  $C_1$ - $C_4$  alkylamino or  $C_1$ - $C_4$  di-alkylamino;

5 X is O, NH or  $CH_2$ ;

Z is a group (a), (b), (c) or (d)



wherein

n is 1, 2, 3 or 4;

m is zero or 1;

10 q is zero, 1 or 2;

$R_4$  is hydrogen,  $C_1$ - $C_6$  alkyl, benzyl, cyclohexylmethyl or

$-\text{CH}_2-\text{CH}_2-\text{SO}_2\text{NH}-\text{R}_6$  in which  $\text{R}_6$  is  $\text{C}_1-\text{C}_6$  alkyl or benzyl;

$\text{R}_5$  is  $\text{C}_1-\text{C}_6$  alkyl; and

T is halogen;

provided that, when Z is defined under (c), then X is O or

5  $\text{CH}_2$ , and their pharmaceutically acceptable salts, for use  
as 5-HT<sub>4</sub> agonists. The compounds of formula (I) can  
therefore be useful in the treatment of all the pathologies  
wherein a stimulation of the 5-HT<sub>4</sub> receptor is needed. As  
an example, the compounds of formula (I) may be useful as  
10 therapeutic prokinetic agents in the treatment of  
gastrointestinal disorders such as, for example, dyspepsia,  
gastro-oesophageal reflux disease (GORD) or gastroparesis.  
The compounds of formula (I) may also be useful, by virtue  
of their 5-HT<sub>4</sub> agonist properties, as cognition activators,  
15 in the treatment of CNS disorders characterized by learning  
and/or memory dysfunctions.

The alkyl, alkoxy and alkylamino groups may be branched or  
straight groups.

Representative examples of  $\text{C}_1-\text{C}_6$  alkyl groups include  
20 methyl, ethyl, *n*- and *iso*-propyl, *n*-, *iso*-, *sec*- and *tert*-  
butyl.

Representative examples of  $\text{C}_1-\text{C}_4$  alkoxy groups include  
methoxy and ethoxy.

A  $\text{C}_1-\text{C}_4$  alkylamino group is, in particular, methylamino or  
25 ethylamino.



A C<sub>1</sub>-C<sub>4</sub> di-alkylamino group is, in particular, dimethylamino or diethylamino.

Halogen includes fluorine, bromine, chlorine or iodine, in particular, chlorine or bromine.

- 5 The pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts with inorganic, e.g. hydrochloric, hydrobromic, sulphuric, and phosphoric acids, or organic, e.g. acetic, propionic, lactic, oxalic, malic, maleic, tartaric, citric, benzoic, mandelic,  
10 salicylic and fumaric acids.

Examples of pharmaceutically acceptable salts of the compounds of formula (I) wherein Z is a group (a) or (b) include quaternary derivatives such as, e.g., the compounds quaternised by compounds of formula R<sub>x</sub>-W wherein  
15 R<sub>x</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl or phenyl-C<sub>1</sub>-C<sub>6</sub>alkyl and W is a radical corresponding to an anion of an acid.

Preferably, R<sub>x</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl or phenyl-C<sub>1</sub>-C<sub>4</sub>alkyl, in particular it is methyl, ethyl, n-propyl, n-butyl, benzyl or phenylethyl.

- 20 Preferably, W is a halide such as, e.g., chloride, bromide or iodide.

Examples of pharmaceutically acceptable salts of the compounds of formula (I) wherein Z is a group (a), (b) or (c) also include internal salts, such as, e.g. N-oxides.

- 25 The compounds of formula (I), their pharmaceutically


acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are also object of the present invention.

5 Compounds of formula (I) wherein Z is a group (c) contain an asymmetric carbon atom and, for this reason, they can exist either as a mixture of optical isomers (racemic mixture) or as a single optical isomers (enantiomers). The enantiomers can be separately synthesised from optically  
10 pure starting material or separated from the racemic mixture in a conventional manner.

The present invention also include within its scope both the metabolites and the pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the compounds  
15 of formula (I).

This invention also refers to a preferred class of compounds within formula (I), as novel compounds.

These compounds, which form a further object of the invention, are compounds of formula (I)



wherein



R<sub>1</sub> is hydrogen;

R<sub>2</sub> is chlorine or bromine;

$R_3$  is amino;

X is O or NH;

Z is a group (a), (b), (c) or (d):



wherein

5  $n$  is 2 or 3;

$m$  is zero or 1;

$q$  is 1 or 2;

$R_4$  is  $\text{C}_3\text{--C}_5$  alkyl or  $\text{---CH}_2\text{---CH}_2\text{---SO}_2\text{NH---CH}_3$ ;

$R_5$  is  $\text{C}_3\text{--C}_5$  alkyl; and


10 T is chlorine or bromine;

provided that, when Z is defined under (c), then X is O;

and their pharmaceutically acceptable salts.

Examples of preferred compounds according to the invention are the following:

- N-[1-butyl-1-azabicyclo[2,2,2]oct-3-yl]-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide bromide;  
(1-azabicyclo[2,2,2]oct-3-yl)-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate;
- 5 (1-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate;  
(1-piperidyl)propyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate;  
(1-piperidyl)ethyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate;
- 10 N-[(1-butyl-piperid-4-yl)methyl]-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide;  
N-[(1-piperidyl)propyl]-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide; and
- 15 N-[(1-piperidyl)ethyl]-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide;
- if the case either as a single isomer or as a mixture of isomers thereof, and the pharmaceutically acceptable salts thereof.
- 20 The compounds of formula (I) can be obtained by a process comprising:
- A) reacting a compound of formula (II)





wherein

E is OH, Cl, Br or 1-imidazolyl, and

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are, each independently, hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, amino, C<sub>1</sub>-C<sub>4</sub> alkylamino or

5 C<sub>1</sub>-C<sub>4</sub> di-alkylamino,

with an amine or an alcohol of formula (III), (IV) or (V)



wherein

Q is OH or NH<sub>2</sub>;

n is 1,2,3 or 4;


10 m is 0 or 1;

q is 0,1 or 2; and

R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, cyclohexylmethyl or -CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>2</sub>-NH-R<sub>6</sub> in which R<sub>6</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl or benzyl

so obtaining a compound of formula (I) wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>6</sub> are as defined above, X is NH or O and Z is a group (a), (b) or (c); or

B) reacting a compound of formula (VI)





wherein

Y is OH, Cl, Br or CH<sub>3</sub>-NH-OCH<sub>3</sub>, and

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are as defined above,

with an organometallic derivative of formula (VII), (VIII)

5 or (IX)



wherein


M is MgBr, MgCl or Li, and

n, m, q, R<sub>4</sub> and R<sub>5</sub> are as defined above,

so obtaining a compound of formula (I) wherein R<sub>1</sub>, R<sub>2</sub> and

10 R<sub>3</sub> are as defined above, X is CH<sub>2</sub> and Z is a group (a), (b) or (c); or

C) reacting a compound of formula (X)



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and X are as defined above, and

X is NH, O or CH<sub>2</sub>,

with an alkyl halide of formula  $R_5T$  wherein  $R_5$  is  $C_1-C_6$  alkyl and T is halogen, so obtaining a compound of formula (I) wherein  $R_1$ ,  $R_2$ ,  $R_3$  are as defined above, X is O, NH, or  $CH_2$  and Z is a group (d) ; and, if desired, when a compound

5 of formula (I) contains an asymmetric carbon atom,

D) resolving the racemic mixture of a compound of formula (I) into the single isomers; and/or, if desired,

E) converting a compound of formula (I) into a pharmaceutically acceptable salt thereof.

10 The reaction of a compound of formula (II) with a compound of formula (III), (IV) or (V) under step A) is an analogy process and can be carried out according to well known methods in the art. For instance, an acyl halide of formula (II) can be reacted with an alcohol or an amine of formula  
15 (III), (IV) or (V) in a suitable organic solvent such as, for instance, dichloromethane, tetrahydrofuran or acetonitrile, at a temperature ranging from about  $0^\circ C$  to about the reflux temperature of the mixture, in the presence of a proton scavenger such as, for instance,  
20 triethylamine, sodium hydrogen carbonate or potassium carbonate.

The reaction of a compound of formula (VI) with a compound of formula (VII), (VIII) or (IX) under step B) can also be carried out according to well known methods in the art. For  
25 instance, an acyl halide of formula (VI) can be reacted

with a Grignard reagent of formula (VII), (VIII) or (IX) in a suitable organic solvent such as, e.g., tetrahydrofuran or diethyl ether in the presence of, e.g., Fe(acetylacetonate), or CuI, at a temperature ranging from  
5 about -78°C to about 30°C.

The reaction of a compound of formula (X) with an alkyl halide  $R_5T$  under step C) can be carried out according to standard methodologies. For instance, a compound of formula (X) can be reacted with a compound  $R_5T$  as defined above, in  
10 the presence of a suitable organic solvent such as, e.g., methanol or ethanol, at a temperature ranging from about 30°C to about the reflux temperature of the mixture.

The carboxylic acids of formulae (II) and (VI) wherein E and Y are OH are either commercially available or known  
15 products.

The acid derivatives (II) and (VI) are either known products (EP 0 234 872 A1 Adria Laboratories Inc. ) or may be prepared from the corresponding acids by methods well known in the art.

20 The alcohols and amines of formulae (III), (IV) and (V) are either commercially available or known products.

The organometallic derivatives of formulae (VII), (VIII) and (IX) can be prepared by standard methodologies from the corresponding alkyl halides which are either commercially  
25 available products or can be easily prepared from the



corresponding alcohols of formulae (III), (IV) and (V). The compounds of formula (X) wherein X is NH are known compounds (EP 0 234 872 A1 Adria Laboratories Inc.).

The alkyl halides of formula  $R_5T$  are commercially available products.

The separation of a mixture of isomers of a compound of the invention into single isomers and the conversion of a compound of formula (I) into a pharmaceutically acceptable salt thereof can be carried out according to well known methods in the art.

As already said, the compounds of the present invention are potent agonists of 5-HT (serotonin) on 5-HT<sub>4</sub> receptors and can therefore be used in the treatment of the pathologies wherein a stimulation of the 5-HT<sub>4</sub> receptor is needed. In particular, as 5-HT<sub>4</sub> agonists are known being stimulant of gastrointestinal motility, the compounds of the present invention can be useful as therapeutic prokinetic agents, for example, in the treatment of gastrointestinal disease such as, for instance, dyspepsia, gastro-oesophageal reflux disease (GORD) or gastroparesis. In addition, in view of the fact that 5-HT<sub>4</sub> receptors are believed to be involved in synaptic plasticity events and in memory processes (CNS Drugs (1994) 1, 6-15), and that it has been demonstrated that 5-HT<sub>4</sub> receptor stimulation facilitates in vivo acetylcholine release in rat frontal cortex (NeuroReport

(1994) 5, 1230-2), another application of the compounds of the invention may also be as cognition activators in the treatment of CNS disorders characterized by learning and/or memory dysfunctions.

5 5-HT<sub>4</sub> receptor affinity of the compounds of the present invention was determined by the inhibition of the binding of the 5-HT<sub>4</sub> receptor radioligand [<sup>3</sup>H]-GR-113808 in rat striatum, according to the method of Grossman et al. (Br.J.Pharmacol., 1993, 109, 618-624).

10 The activity of the compounds of the present invention as 5-HT<sub>4</sub> agonists was evaluated "in vitro" by the receptor-mediated relaxation responses of rat, carbachol precontracted oesophageal muscolaris mucosae, following the method of Baxter et al., (Naunhyn Schmiedeberg's Arch. Pharmacol., 1991, 343, 439-446).

As an example, a representative group of compounds according to this invention, namely

(S) - (+) - N - [1-butyl-1-azabicyclo[2,2,2]oct-3-yl] - 4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide bromide  
20 monohydrate (internal code FCE 28773A);  
(1-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate hydrochloride  
(internal code FCE 29029A);  
N - [(1-butyl-piperid-4-yl)methyl] - 4-amino-5-chloro-2,3-  
25 dihydrobenzo[b]furan-7-carboxamide hydrochloride

- (internal code FCE 29030A);
- (1-piperidyl)ethyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate hydrochloride hemihydrate (internal code FCE 29032A);
- 5 N-[(1-piperidyl)ethyl]-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide hydrochloride hydrate (internal code FCE 29033A);
- (1-piperidyl)propyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate hydrochloride
- 10 hemihydrate (internal code FCE 29031A);
- N-[(1-piperidyl)propyl]-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide hydrochloride hydrate (internal code FCE 29034A) and
- (S)-(+)-(1-azabicyclo[2,2,2]oct-3-yl)-4-amino-5-chloro-
- 15 2,3-dihydrobenzo[b]furan-7-carboxylate hydrochloride (internal code FCE 28797A);
- were tested according to the methods described above and the obtained results are reported on Table 1.

Table 1

20	Compound	Binding assay $K_i$ (nM)	5-HT <sub>4</sub> R activity $EC_{50}$ (nM)
	FCE 28773A	1.9	8.5 (i.a.=0.52)
	FCE 29029A	0.13	5.67 (i.a.=1.0)
	FCE 29030A	1.9	4.49 (i.a.=0.59)

5	FCE 29032A	0.94	2.02 (i.a.=0.71)
	FCE 29033A	41	35.4 (i.a.=0.65)
	FCE 29031A	4.5	7.43 (i.a.=0.70)
	FCE 29034A	9.6	19.3 (i.a.=0.60)
	FCE 28797A	8.3	11.1 (i.a.=0.71)

$$K_i = \frac{IC_{50}}{1 + \frac{[L]}{K_d}}$$

10 where

$IC_{50}$  = concentration of the tested compound which forces the displacements of 50% of the bound radioligand concentration, obtained in the absence of inhibitor.

$[L]$  = radioligand concentration

15  $K_d$  = dissociation constant of the radioligand-receptor complex.

$EC_{50}$  = efficacy concentration: concentration of the tested compound which induces 50% of the max. response (in this case 50% of the max. relaxation).

20 i.a. = intrinsic activity: max. response/max response of the natural agonist (in this case max. relaxation/5-HT max.relaxation).

The tabulated results clearly show that the compounds of the invention exhibit high affinity for the 5-HT<sub>1</sub> receptor  
25 sites and, in the same time, are particularly effective in

promoting 5-HT<sub>1</sub> receptor activity.

The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid  
5 solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous injection or infusion.

The dosage depends on the age, weight, conditions of the patient and on the administration route; for example, the  
10 dosage adopted for oral administration to adult humans e.g. for the representative compound of the invention FCE 29034A may range from about 1 to about 500 mg pro dose, from 1 to 5 times daily.

The invention includes pharmaceutical compositions  
15 comprising a compound of the invention as an active principle in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional  
20 methods and are administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, destrose, saccharose, cellulose, corn starch or potato starch;  
25 lubricants, e.g. silica, talc, stearic acid, magnesium or

calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

The liquid dispersion for oral administration may be e.g. syrups, emulsions and suspension.

The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.

The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol,

and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

The following examples illustrate but do not limit the invention.

#### Example 1

A mixture of 4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylic acid (0.700g , 3.28 mmol) and carbonyldiimidazol (0.580g , 3.60 mmol) in 10 ml of anhydrous tetrahydrofuran was heated at 40°C for 1.5h. Afterward (1-piperidyl)ethylamine (0.427ml , 4.92mmol) in 5ml of tetrahydrofuran was added, the mixture was heated for additional 2h and stirred at 22°C for 16h. Volatiles were evaporated under reduced pressure and the residue was taken up with water and ethyl acetate; the layers were separated, the organic layer was dried over anhydrous sodium sulphate and evaporated to give 1.0 of raw material, which was partially purified by column chromatography over silica gel

(eluant chloroform/methyl alcohol/ammonia solution 30% 46:4:0.1). The carboxamide was conveniently isolated as its hydrochloride by adding to the free base in acetone/isopropyl alcohol 1 equivalent of hydrochloric acid in isopropyl alcohol. Precipitated solid was filtered, washed with diethyl ether and dried, yielding 746mg (60%) of N-[(1-piperidyl)ethyl]-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide hydrochloride hydrate as a colorless solid (m.p. = 237-239°C).

10 Analogously, the following compounds were prepared :  
N-[(1-piperidyl)propyl]-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide hydrochloride hydrate (m.p. 192-194°C); and  
N-[(1-butyl-piperid-4-yl)methyl]-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide hydrochloride (m.p. 260-262°C).

15

### Example 2

A mixture of 4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylic acid (1.61g , 7.56 mmol) and carbonyldiimidazole (1.35g , 8.32 mmol) in 15 ml of anhydrous tetrahydrofuran was heated at 40°C for 1.5h. Afterward a solution of N-(1-butyl-piperid-4-yl)methyl alcohol (2.59g , 15.1mmol) and 1,8-diazabicyclo[5,4,0]undec-7-en (DBU) (1.13ml , 7.56 mmol) in 10ml of tetrahydrofuran was added and the mixture was heated for additional 2.5h. Volatiles were evaporated

20

25



under reduced pressure and the residue was taken up with water and diethyl ether; the layers were separated, the organic layer was dried over anhydrous sodium sulphate and evaporated to give 3.5g of raw material, which was purified  
5 by column chromatography over silica gel (eluant chloroform/methyl alcohol 46:4) yielding 1.5g (54%) of (1-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate (m.p. = 124-126°C) as a colorless solid.

10 Analogously, the following compounds can be prepared :  
(1-piperidyl)ethyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate (m.p. = 152-154°C);  
(1-piperidyl)propyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate; and  
15 (S) - (+) - (1-azabicyclo[2,2,2]oct-3-yl) -4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate.

### Example 3

1 equivalent of hydrochloric acid in isopropyl alcohol was added at 5°C to a stirred solution of (1-piperidyl)propyl  
20 4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate (337mg , 0.996mmol) in acetone . Precipitated solid was filtered, washed with diethyl ether and dried, yielding 342mg (89%) of (1-piperidyl)propyl 4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate hydrochloride  
25 hemihydrate as a colorless solid (m.p. = 226-228°C).

Analogously, the following compounds were prepared :

(1-piperidyl)ethyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate hydrochloride hemihydrate (m.p. 255-257°C);

5 (1-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate hydrochloride (m.p. = 238-240°C); and

(S) - (+) - (1-azabicyclo[2,2,2]oct-3-yl) -4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate hydrochloride  
10 (m.p. 283.5-284.5);  $[\alpha]_D^{23} = +82$  (c = 0.94 , DMF).

#### Example 4

A mixture of (S) - (+) - [1-azabicyclo[2,2,2]oct-3-yl] -4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide (0.508g , 1.58mmol) and n-butylbromide (0.169ml ,  
15 1.58mmol) in ethyl alcohol was heated under reflux for 16h. The solvent was removed under reduced pressure, the residue was purified by column chromatography over silica gel (eluent chloroform/ methyl alcohol 4:1) and crystallized by water giving 0.43g (60%) of (S) - (+) - N-[1-  
20 butyl-1-azabicyclo[2,2,2]oct-3-yl] -4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide bromide monohydrate as an amorphous colorless solid ;  $[\alpha]_D^{23} = +36$  (c = 0.94 , DMF).


Example 5

With the usual methods of pharmaceutical technique, preparation can be made of capsules having the following composition:

5	N-(1-piperidyl)ethyl-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide hydrochloride	
	hydrate	50mg
	talc	2mg
	starch	2mg
10	microcristalline cellulose	6mg
	magnesium stearate	1mg



CLAIMS

1. A dihydrobenzofuran derivative of formula (I)



wherein

- $R_1$ ,  $R_2$  and  $R_3$  are, each independently, hydrogen,  
 5  $C_1$ - $C_6$  alkyl, halogen, hydroxy,  $C_1$ - $C_4$  alkoxy, amino,  
 $C_1$ - $C_4$  alkylamino or  $C_1$ - $C_4$  di-alkylamino;  
 $X$  is O, NH or  $CH_2$ ;  
 $Z$  is a group (a), (b), (c) or (d)



wherein

n is 1, 2, 3 or 4;

m is zero or 1;

q is zero, 1 or 2;

- 5  $R_4$  is hydrogen,  $C_1$ - $C_6$  alkyl, benzyl, cyclohexylmethyl or  $-CH_2-CH_2-SO_2NH-R_6$  in which  $R_6$  is  $C_1$ - $C_6$  alkyl or benzyl;


$R_5$  is  $C_1$ - $C_6$  alkyl; and

T is halogen;

provided that, when Z is defined under (c), then X is O

- 10 or  $CH_2$ ; or a pharmaceutically acceptable salt thereof,  
for use as a 5-HT<sub>4</sub> receptor agonist.

2. A dihydrobenzofuran derivative of formula (I):



wherein

$R_1$  is hydrogen;



- 15  $R_2$  is chlorine or bromine;

$R_3$  is amino;

X is O or NH;

Z is a group (a), (b), (c) or (d)

26



wherein

n is 2 or 3;

m is zero or 1;

q is 1 or 2;

5  $R_4$  is  $C_3$ - $C_5$  alkyl or  $-CH_2-CH_2-SO_2NH-CH_3$ ;

$R_5$  is  $C_3$ - $C_5$  alkyl; and

T is chlorine or bromine;

provided that, when Z is defined under (c), then X is O;

or a pharmaceutically acceptable salt thereof.

10 3. A compound as claimed in claim 2, selected from:

N-[1-butyl-1-azabicyclo[2,2,2]oct-3-yl]-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxamide bromide;

(1-azabicyclo[2,2,2]oct-3-yl)-4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylate;

15 (1-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2,3-

dihydrobenzo[b]furan-7-carboxylate;

(1-piperidyl)propyl-4-amino-5-chloro-2,3-dihydrobenzo

- [b] furan-7-carboxylate;  
(1-piperidyl)ethyl-4-amino-5-chloro-2,3-dihydrobenzo  
[b] furan-7-carboxylate;  
N-[(1-butyl-piperid-4-yl)methyl]-4-amino-5-chloro-2,3-  
5 dihydrobenzo[b]furan-7-carboxamide;  
N-[(1-piperidyl)propyl]-4-amino-5-chloro-2,3-  
dihydrobenzo[b]furan-7-carboxamide; and  
N-[(1-piperidyl)ethyl]-4-amino-5-chloro-2,3-  
dihydrobenzo[b]furan-7-carboxamide;  
10 if the case either as a single isomer or as a mixture of  
isomers, and the pharmaceutically acceptable salts  
thereof.
4. A compound as claimed in claim 2 or 3 for use as a  
5HT<sub>4</sub> receptor agonist.
- 15 5. A compound as claimed in claim 1, 2 OR 3 for use as a  
5-HT<sub>4</sub> receptor agonist in the treatment of a pathology  
wherein stimulation of a 5-HT<sub>4</sub> receptor is needed.
6. A compound as claimed in claim 1, 2 or 3 for use as  
a therapeutic prokinetic agent in the treatment of  
20 gastrointestinal disorders.
7. A compound as claimed in claim 6 wherein the


gastrointestinal disorder is dyspepsia, gastro-oesophageal reflux disease (GORD) or gastroparesis.

8. A compound as claimed in claim 1, 2 or 3 for use as a cognition activator in the treatment of CNS disorders  
5 characterized by learning and/or memory dysfunctions.

9. Use of a compound as defined in claim 1, 2, or 3 in the preparation of a medicament for use as a 5HT<sub>4</sub> receptor agonist.

10. A process for preparing a dihydrobenzofuran derivative of formula (I) as defined in claim 1 or 2, or a pharmaceutically acceptable salt thereof, said process comprising:

A) reacting of a compound of formula (II)






wherein

15 E is OH, Cl, Br or 1-imidazolyl, and  
R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are, each independently, hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, amino,



C<sub>1</sub>-C<sub>4</sub> alkylamino or C<sub>1</sub>-C<sub>4</sub> di-alkylamino,  
with an amine or an alcohol of formula (III), (IV) or (V)



wherein

Q is OH or NH<sub>2</sub>;

5 n is 1,2,3 or 4;


m is 0 or 1;

q is 0,1 or 2; and

R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, cyclohexylmethyl or  
-CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>2</sub>NH-R<sub>6</sub> in which R<sub>6</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl or benzyl,

10 so obtaining a compound of formula (I) wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>  
and R<sub>6</sub> are as defined above, X is NH or O and Z is a  
group (a), (b) or (c); or



B) reacting a compound of formula (VI)



wherein


15 Y is OH, Cl, Br or CH<sub>3</sub>-NH-OCH<sub>3</sub>, and

$R_1$ ,  $R_2$  and  $R_3$  are as defined above,  
with an organometallic derivative of formula (VII),  
(VIII) or (IX)



wherein

- 5 M is MgBr, MgCl or Li, and  
n, m, q,  $R_4$  and  $R_5$  are as defined above,  
so obtaining a compound of formula (I) wherein  $R_1$ ,  $R_2$  and  
 $R_3$  are as defined above, X is  $CH_2$  and Z is a group (a),  
(b) or (c); or  
10 C) reacting a compound of formula (X)



wherein

$R_1$ ,  $R_2$ ,  $R_3$  and X are as defined above, and  
X is NH, O or  $CH_2$ ,  
with an alkyl halide of formula  $R_5T$  wherein  $R_5$  is

C<sub>1</sub>-C<sub>6</sub> alkyl and T is halogen, so obtaining a compound of formula (I) wherein R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are as defined above, X is O, NH or CH<sub>2</sub> and Z is a group (d); and, if desired, when a compound of formula (I) contains an asymmetric

5 carbon atom,

D) resolving the racemic mixture of a compound of formula (I) into the single isomers; and/or, if desired,

E) converting a compound of formula (I) into a pharmaceutically acceptable salt thereof.

10 11. A pharmaceutical composition comprising a carrier and/or a pharmaceutically acceptable diluent and, as an active substance, a compound as defined in claim 1, 2 or 3.

12. A pharmaceutical composition according to claim 11,  
15 for use in the treatment of a pathology wherein stimulation of a 5HT<sub>4</sub> receptor is needed.

13. A pharmaceutical composition according to claim 11, for use as a therapeutic prokinetic agent in the treatment of gastrointestinal disorders.

20 14. A pharmaceutical composition according to claim 13 wherein the gastrointestinal disorder is dyspepsia,

gastro-oesophageal reflux disease (GORD) or  
gastroparesis.

15. A pharmaceutical composition according to claim 11  
for use as a cognition activator in the treatment of CNS  
5 disorders characterized by learning and/or memory  
dysfunctions.

## INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/EP 96/01482

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D307/79 C07D405/12 A61K31/445 C07D453/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	BIOORG. MED. CHEM. LETT. (BMCLE8,0960894X);96; VOL.6 (3); PP.263-6, PHARM. & UPJOHN;CNS PRECLIN. R&D; NERVIANO; 20014; ITALY (IT), XP002007988 FANCELLI D ET AL: "Serotoninerbic 5-HT3 and 5-HT4 receptor activities of dihydrobenzofuran carboxylic acid derivatives" see the whole document --- -/--	1-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

22 July 1996

Date of mailing of the international search report

14.08.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Scruton-Evans, I

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/01482

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEM. PHARM. BULL. (CPBTAL,00092363);94; VOL.42 (1); PP.95-100, YOSHITOMI PHARM. IND. LTD.;RES. LAB.; FUKUOKA; 871; JAPAN (JP), XP002007989 KUROITA T ET AL: "Synthesis and structure-activity relationships of 2,3-dihydrobenzofuran-7-carboxamide derivatives as potent serotonin-3 (5-HT3) receptor antagonists" see the whole document ---	1-15
X	WO,A,94 26314 (C JOHN ) 24 November 1994  see example 2 and claims 1 and 40 ---	1,5-8, 10-15
Y	US,A,5 122 528 (A IMONDI) 16 June 1992 see whole document, especially the compounds of column 16 ---	1-15
X	EP,A,0 445 862 (JANSSEN PHARMACEUTICA) 11 September 1991 see general formula I ---	1,5-8, 10-15
X	PATENT ABSTRACTS OF JAPAN vol. 13, no. 326 (C-620), 24 July 1989 & JP,A,01 104072 (YOSHITOMI PHARMACEUTICAL INDUSTRY LTD), 21 April 1989, see definitions of X and R4 see abstract ---	1,5-8, 10-15
X	WO,A,93 16072 (SMITHKLINE BEECHAM PLC) 19 August 1993 cited in the application see whole document, especially example 2 ---	1,5-8, 10-15
Y	BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 3, no. 4, 1993, pages 633-634, XP000576640 G.S.BAXTER ET AL: "Quaternised Renzapride as a potent and selective 5-HT4 receptor agonist" see the whole document -----	1-15

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/01482

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9426314	24-11-94	EP-A- 0650372	03-05-95
US-A-5122528	16-06-92	US-A- 4888353	19-12-89
		AU-B- 1402092	08-10-92
		CA-A- 2063912	06-10-92
		EP-A- 0507637	07-10-92
		JP-A- 6172172	21-06-94
		CA-A- 1297877	24-03-92
		EP-A- 0147044	03-07-85
		JP-B- 6084365	26-10-94
		JP-A- 60169473	02-09-85
		US-A- 5175173	29-12-92
		US-A- 5126364	30-06-92
		CA-A- 1301170	19-05-92
		DE-A- 3774727	09-01-92
		EP-A- 0234872	02-09-87
		JP-A- 62234083	14-10-87
EP-A-445862	11-09-91	AU-B- 636012	08-04-93
		AU-B- 7207991	12-09-91
		BG-B- 60381	31-01-95
		CA-A- 2037575	07-09-91
		CN-A- 1054598	18-09-91
		CN-A- 1054778	25-09-91
		HR-A- 930483	31-12-95
		IL-A- 97018	27-11-95
		JP-A- 4211685	03-08-92
		LT-A,B 846	27-02-95
		LV-B- 10085	20-02-95
		NO-B- 177424	06-06-95
		PL-B- 168811	30-04-96
		PL-B- 168384	29-02-96
		PL-B- 168686	29-03-96
		PL-B- 168356	29-02-96
		US-A- 5185335	09-02-93
		US-A- 5262418	16-11-93
WO-A-9316072	19-08-93	AP-A- 373	07-12-94
		AU-B- 668102	26-04-96
		AU-B- 2541892	05-04-93

**INTERNATIONAL SEARCH REPORT**

information on patent family members

Intern al Application No

PCT/EP 96/01482

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9316072		AU-B- 3457293	03-09-93
		BR-A- 9206599	08-11-94
		CA-A- 2118812	18-03-93
		CA-A- 2129112	19-08-93
		CN-A- 1073173	16-06-93
		CZ-A- 9400560	13-07-94
		EP-A- 0604494	06-07-94
		EP-A- 0625149	23-11-94
		FI-A- 941178	11-03-94
		WO-A- 9305038	18-03-93
		HU-A- 70154	28-09-95
		JP-T- 6510537	24-11-94
		JP-T- 7503480	13-04-95
		NO-A- 940874	11-03-94
		NZ-A- 244282	28-08-95
		NZ-A- 246915	28-05-96
		SK-A- 30294	07-12-94
		ZA-A- 9300764	26-11-93
-----			